Skip to main content
ACAD
NASDAQ Life Sciences

Acadia Lifts 2026 Outlook as DAYBUE STIX Demand Drives 16% Revenue Jump

Tom Rudovsky · Reported by Reuters
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$27.15
Mkt Cap
$4.649B
52W Low
$19.69
52W High
$28.35
52W Position info
38% above low
Off High info
4.2% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

ACAD sits 38% above its 52-week low of $19.69.

Summary

Acadia's Q2 revenue rose 16% year-over-year to $307.96 million, fueled by strong demand for DAYBUE STIX and NUPLAZID. Net income swung to $31.5 million from a prior-year loss, and the company raised its full-year 2026 revenue guidance to $1.24-$1.30 billion, with DAYBUE sales now seen at $480-$510 million. This follows the positive EU opinion for DAYBUE in June and the recent Fast Track designation for remlifanserin, reinforcing the commercial momentum. The raised outlook and upcoming Phase 2 Alzheimer's psychosis data in September-October provide clear catalysts for further upside.

At the time of this announcement, ACAD was trading at $27.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6B. The 52-week trading range was $19.69 to $28.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

ACAD - Latest Insights

ACAD
Nov 16, 2026, 1:38 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $18.79
Real-time Price: $17.12 info
Change: -$1.67 (-9%) info
Market Cap: $2.957B info
ACAD
Nov 04, 2026, 6:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.95
Real-time Price: $17.12 info
Change: -$4.83 (-22%) info
Market Cap: $2.957B info
ACAD
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.46
Real-time Price: $17.12 info
Change: -$4.34 (-20%) info
Market Cap: $2.957B info
ACAD
Oct 05, 2026, 2:23 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $20.07
Real-time Price: $17.12 info
Change: -$2.95 (-15%) info
Market Cap: $2.957B info
ACAD
Sep 28, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.53
Real-time Price: $17.12 info
Change: -$3.41 (-17%) info
Market Cap: $2.957B info